Spring Bank Pharmaceuticals, Inc. announced that it has initiated dosing patients in a Phase 1 trial of SB 11285, the company’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist. The Phase 1 trial aims to evaluate safety, tolerability and initial anti-tumor activity of IV SB 11285 in patients with advanced solid tumors. SB 11285 is a novel STING agonist immunotherapeutic agent designed and developed for IV administration being investigated for the treatment of selected cancers such as certain breast cancers, lung cancers, colo-rectal cancers and melanoma. In vitro and in vivo preclinical findings indicate that SB 11285 could be used to target a variety of tumors at various anatomic sites and has the potential to enhance the activity of other therapeutic modalities such as immune checkpoint inhibitors, PARP inhibitors and other chemotherapeutics.